Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (863)	8/18/2003 6:36:32 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

Press Release Source: Genentech Genentech Presents Positive Preliminary Six-Month Data from Phase Ib/II Study for Lucentis in Age-Related Macular Degeneration --AMD-- Monday August 18, 4:59 pm ET -- Two Randomized Phase III Clinical Trials Currently Enrolling Patients -- NEW YORK--(BUSINESS WIRE)--Aug. 18, 2003-- Genentech (NYSE:DNA - News) today announced preliminary data from the extension phase of an open-label Phase Ib/II randomized, single-agent study with the investigational anti-angiogenesis product, Lucentis(TM) (ranibizumab), formerly known as rhuFab V2, for patients with the wet form of age-related macular degeneration (AMD). Lucentis is a humanized, therapeutic antibody fragment that is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in angiogenesis, the formation of new blood vessels and in regulating vascular permeability. Data from this study is being presented today at The 21st Annual Meeting of the American Society of Retina Specialists in New York City. "The data from this study appear to indicate that most patients not only continued to maintain vision, but improved their vision when Lucentis therapy was extended to six months and beyond," said Hal Barron, M.D., FACC, Genentech's vice president, Medical Affairs. "Furthermore, patients initially showing a decline in visual acuity in the usual care group experienced an improvement in visual acuity upon crossing over to receive Lucentis. The fact that visual acuity continued to improve during extended Lucentis treatment suggests that a patient's response can be durable, an important potential benefit for patients with this normally progressive disease." In the first treatment period (98 days), 64 patients with minimally classic and predominantly classic wet AMD were entered into the single-agent, multi-center trial. Patients were treated every four weeks for four doses (either 300 or 500 micrograms) of Lucentis (n=53) or with usual care of observation or photodynamic therapy (n=11). After Day 98, patients in the usual care group were permitted to cross over to receive Lucentis. All patients were monitored for safety and visual acuity, which is defined as the total number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. Stable vision is defined as losing or gaining fewer than 15 letters on the ETDRS chart compared with the baseline. Of the 53 patients who received Lucentis during the first treatment period, 42 patients continued with Lucentis for the second treatment period with 40 patients completing the study through Day 210. The visual acuity at Day 98 in patients who continued with treatment improved by an average of 7.4 letters (n=20) in the 300 microgram group and 12.6 letters (n=22) in the 500 microgram group. At Day 210, their visual acuity improved further to an average gain of 12.8 letters (n=19) in the 300 microgram group and 15.0 letters (n=21) in the 500 microgram group compared with the baseline. While patients receiving usual care demonstrated an average loss in visual acuity of 5.1 letters (n=11) at Day 98, those who crossed over to Lucentis improved on the average by 7.3 letters (n=4) and 3.2 letters (n=5) at Day 210 compared with the baseline in the 300 and 500 microgram groups, respectively. Of the 40 patients who were treated with Lucentis for six months and completed the study through Day 210, 97.5 percent (n=39) of patients had stable or improved vision at Day 210, of which 45 percent (n=18) improved 15 letters or more on the ETDRS chart. The most common side effects from treatment with Lucentis were mild transient, reversible inflammation. Adverse events were similar in the first and extended treatment periods. There were three serious adverse events of endophthalmitis (infection), recurrent uveitis (inflammation) and central retinal vein occlusion, all of which were successfully treated or resolved. Phase III Clinical Trials Currently Enrolling Genentech is currently enrolling patients into two Phase III clinical trials for Lucentis. The first trial, called MARINA, is a randomized, multi-center, double-masked, sham-injection controlled study evaluating the safety and efficacy of two different doses of Lucentis in approximately 720 patients with minimally classic or occult wet AMD. The second trial, called ANCHOR, is a randomized, multi-center, double-masked, active treatment-controlled, Phase III study comparing two different doses of Lucentis to verteporfin photodynamic therapy in approximately 426 patients with predominantly classic wet AMD. For more information on these clinical trials, please call 1-888-662-6728.

To: Miljenko Zuanic who wrote (863)	11/12/2003 10:27:10 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

REGN continue to draw from 2003-Novartis loan, from $5.1 M to $9.2 M. (from 10Q) <<Development expenses incurred during 2003 will be shared equally by Regeneron and Novartis. We may fund our share of 2003 expenses through a loan from Novartis that will be forgiven, together with accrued interest, should certain preclinical and clinical milestones be reached and is otherwise payable on July 1, 2004. As of September 30, 2003, we have drawn $9.2 million against this loan facility. In addition, at September 30, 2003, $3.9 million was receivable from Novartis for their share of IL-1 Trap development expenses incurred by Regeneron during the third quarter of 2003.>> Do they think that specific milestones will be reached? Or interest on this loan is too low not to pass? Bit's me!